Exciting Update in Medical Toxicology!

ToxIC, initially launched as a prospective multi-center registry of medical toxicology consultations, has now surpassed 100,000 cases. This milestone underlines its crucial role in advancing our understanding of toxicological emergencies. The Core Registry has paved the way for several sub-registries, including the North American Snakebite Registry and the Medications for Opioid Use Disorder sub-registry, addressing a variety of research questions within medical toxicology.

 

ToxIC's portfolio also includes impressive non-registry-based projects, such as:

• FDA-ACMT COVID-19 ToxIC Pharmacovigilance Project: Identifying adverse drug reactions related to COVID-19 treatments.

• Fentalog Study: A toxico-surveillance study of suspected opioid overdose cases.

• Drug Overdose Toxico-Surveillance Reporting Program: Enrolling suspected stimulant or opioid overdose cases.

• Real-World Examination of Naloxone for Drug Overdose Reversal Project: Just launched to provide critical insights into naloxone's effectiveness in real-world settings.

 

With its extensive experience in multi-center studies and a robust infrastructure, ToxIC is well-equipped to rapidly respond to emerging toxicological threats, enhance drug and chemical toxicosurveillance, and address other pressing medical toxicology priorities.

 

Congratulations to the authors Jeffrey Brent, Paul Wax, Rachel Culbreth, Sharan Campleman, and Kim Aldy for this remarkable achievement. We look forward to the continued advancements and contributions from ToxIC in the field of medical toxicology.

 

Read the full study here: DOI: 10.1007/s13181-024-01020-1